Ventricular assist device: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(111 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{SI}}
{{SI}}


'''Editor-In-Chief:''' Marv Slepian, M.D.; University of Arizona [mailto:slepian@email.arizona.edu]; Juan A. Sanchez MD MPA [mailto:Juan.Sanchez@stmh.org], Chairman, The Stanley J. Dudrick Department of Surgery, Saint Mary's Hospital, Waterbury, CT
{{CMG}}
{{AE}} Marv Slepian, M.D.; University of Arizona [mailto:slepian@email.arizona.edu]; Juan A. Sanchez MD MPA [mailto:Juan.Sanchez@stmh.org], Chairman, The Stanley J. Dudrick Department of Surgery, Saint Mary's Hospital, Waterbury, CT, [[User:Tayebah Chaudhry|Tayebah Chaudhry]][mailto:dr.thch@yahoo.com],  {{HK}}


{{ACMG}}


==Overview==
==Overview==
A '''Ventricular assist device''', or '''VAD''', is a type of [[artificial heart]] or assisted circulation<ref>{{MeSH|Assisted circulation}}</ref> that is a mechanical device that is used to partially or completely replace the function of a failing [[heart]]. Some VADs are intended for short term use, typically for patients recovering from [[myocardial infarction|heart attacks]] or [[cardiac surgery | heart surgery]], while others are intended for long term use (months to years and in some cases for life), typically for patients suffering from [[Heart Failure | congestive heart failure]].
'''Ventricular assist device''' '''(VAD)''' is a [[mechanical device]] that provides Mechanical [[Circulatory Support]] ([[MCS]]) in patients with advanced [[heart failure]]. VAD [[therapy]] has shown improved outcome and survival in heart failure patients compared to [[pharmacological]] therapy alone. These devices are commonly used as a Bridge-to-Transplant (BTT) in [[heart transplant]] eligible patients or as a Destination Therapy (DT) in patients ineligible for heart transplant. VADs are indicated for either short-term use in patients recovering from [[heart attack]]s or heart surgery or for long-term use (months to years and in some cases for life) in patients suffering from [[end-stage heart failure]].


VADs need to be clearly distinguished from [[artificial heart]]s, which are designed to completely take over cardiac function and generally require the removal of the patient's heart.
Over the years, significant development has been made to create miniaturized VADs with increased durability, reliability and lesser noise emission. Newer (third generation) VADs are Continuous Flow (CF) pumps with lesser [[complications]] compared to the older (first generation) VADs that were large and had pulsatile-flow pumps.
Depending on the [[heart chamber]] that needs MCS, VADs can be used as [[Left Ventricular Assist]] Devices (LVADs), [[Right Ventricular]] Assist Devices (RVADs) or BiVentricular Assist Devices (BiVADs).


VADs are designed to assist either the right (RVAD) or left (LVAD) [[Ventricle (heart)|ventricle]], or both at once (BiVAD). The choice of device depends on the underlying [[heart disease]] and the pulmonary arterial resistance which determines the load on the right ventricle. LVADs are most commonly used but when pulmonary arterial resistance is high, right ventricular assist becomes necessary. Long term VADs are normally used to keep patients alive with a good quality of life while they wait for a heart transplant (bridge to transplant).  However, LVADs are sometimes used as destination therapy sometimes as a bridge to recovery.
Some VADs are percutaneous or transcutaneous ([[Impella]], [[TandemHeart]]) while others are [[implantable]] ([[HeartMate]] II, [[HeartMate III]]), that allow patients to be fully mobile.


[[Clinical practice guideline]]s suggest roles<ref name="pmid25861963">{{cite journal| author=Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK et al.| title=2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. | journal=J Am Coll Cardiol | year= 2015 | volume= 65 | issue= 19 | pages= e7-e26 | pmid=25861963 | doi=10.1016/j.jacc.2015.03.036 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25861963  }} </ref>.
Ongoing research in VAD development is being focused on eliminating the need for a driveline, better surgical approaches and strategies for [[telemetric assessment]] of device function and remote charging of batteries.


VADs can be:
==History==
* Percutaneous or transcutaneous. Examples include<ref name="pmid25861963">{{cite journal| author=Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK et al.| title=2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. | journal=J Am Coll Cardiol | year= 2015 | volume= 65 | issue= 19 | pages= e7-e26 | pmid=25861963 | doi=10.1016/j.jacc.2015.03.036 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25861963  }} </ref>
 
** Axial flow pumps, such as Impella
VADs evolved over time after an external technology was used to provide [[cardiovascular]] support to a [[patient]] with [[Cardiopulmonary bypass]] ([[CPB]]) in an [[atrial septal defect]] repair surgery by John Gibbons. This lead to further interest and efforts to developing an [[artificial]] heart and later implantation of VAD in the late 1960s. Thoratec pneumatic VAD was the first [[Food and Drug Administration]] ([[FDA]]) approved VAD used as a BTT. This technology further evolved into HeartMate I, but more work needed to be done to develop newer LVADs with lesser complications. The Second and Third Generation VADs were designed to have a continuous flow rather than pulsatile. <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
** Left atrial to femoral artery bypass pumps, such as the TandemHeart
 
* Implantable that allows a patient to be fully mobile. Examples include:
==Types of Ventricular Assist Devices (VADs)==
** HeartMate II which is a continuous-flow system with mechanical bearings
 
** HeartMate III which is a magnetically levitated device that is a pulsatile-flow system without mechanical bearings
VADs are implanted in one ventricle or both [[ventricles]] of [[heart]].
 
====Left Ventricular Assist Device (LVAD)====
 
* LVADs are the most commonly implanted VADs in end-stage heart failure patients. With robust innovation in technology, LVADs have significantly increased patient survival despite the [[adverse events]] associated with the devices. This has lead to growing proportion of patients undergoing LVAD implantations as a Destination therapy.
 
* LVADs unload [[left ventricle]] and augment the [[cardiac outflow]] (nearly 10L/min) into the [[ascending aorta]].
 
* HeartMate II, HeartMate III and HeartWare HVAD are the only commercially FDA- approved LVADs for adults in North America. Worldwide efforts are being made to create the most effective and safest interface including the [[INCOR]], [[Jarvik 2000]], [[EVAHEART LVAS]] and more. <ref name="pmid30565993">{{cite journal |vauthors=Han JJ, Acker MA, Atluri P |title=Left Ventricular Assist Devices |journal=Circulation |volume=138 |issue=24 |pages=2841–2851 |date=December 2018 |pmid=30565993 |doi=10.1161/CIRCULATIONAHA.118.035566 |url=}}</ref>
 
====Right Ventricular Assist Device (RVAD)====
 
* RVADs may be needed in the management of [[Right ventricular failure]] (RVF) for mechanical [[circulatory]] support. RVF can be from a [[primary cause]], for example, [[acute right ventricular infarction]], increased [[afterload]] resulting from [[acute pulmonary embolism]] or [[chronic pulmonary hypertension]], [[congenital heart disease]], or it can be from a [[secondary cause]], for example, post-[[cardiotomy]] (commonly as a complication of LVAD implantation). <ref name="pmid30093192">{{cite journal |vauthors=Pieri M, Pappalardo F |title=Impella RP in the Treatment of Right Ventricular Failure: What We Know and Where We Go |journal=J. Cardiothorac. Vasc. Anesth. |volume=32 |issue=5 |pages=2339–2343 |date=October 2018 |pmid=30093192 |doi=10.1053/j.jvca.2018.06.007 |url=}}</ref>
 
* RVADs are implanted surgically or [[percutaneously]]. [[Impella RP]] is an example of [[minimally invasive]] percutaneous RVAD. The pump has an inflow in the [[inferior vena cava]] and outflow in the [[pulmonary artery]].
 
====BiVentricular Assist Device (BiVAD)====
 
*BiVAD is used to provide simultaneous MCS to both ventricles of heart. It is different from [[Total Artificial Heart]] (TAF) since it works in parallel to the native heart and removal of native heart is not required. Hence, BiVAD provides a potential for [[myocardial]] recovery of the retained native heart and reduces the need for a [[donor]] heart.<ref name="GregoryTimms2011">{{cite journal|last1=Gregory|first1=Shaun D.|last2=Timms|first2=Daniel|last3=Gaddum|first3=Nicholas|last4=Mason|first4=David G.|last5=Fraser|first5=John F.|title=Biventricular Assist Devices: A Technical Review|journal=Annals of Biomedical Engineering|volume=39|issue=9|year=2011|pages=2313–2328|issn=0090-6964|doi=10.1007/s10439-011-0348-8}}</ref>
 
*BiVAD may be indicated in [[right ventricular dysfunction]] after LVAD implantation. However, early and/or long-term dual VAD therapy for biventricular support may be considered in evident right ventricular failure and conditions like [[acute circulatory collapse]] due to [[fulminant myocarditis]], acute decompensation of [[dilated]] biventricular [[cardiomyopathy]], massive [[Myocardial Infarction]] (involving the septum or RV), acute deterioration following [[toxic cardiomyopathy]], [[infiltrative cardiomyopathy]] or RV cardiomyopathies with concomitant involvement of the left ventricle.<ref name="HaywardShehab2019">{{cite journal|last1=Hayward|first1=Christopher S|last2=Shehab|first2=Sajad|title=Choosing Between Left Ventricular Assist Devices and Biventricular Assist Devices|journal=Cardiac Failure Review|volume=5|issue=1|year=2019|pages=19|issn=2057-7540|doi=10.15420/cfr.2018.23.2}}</ref>
 
*Examples of VADs implanted as BiVAD include Abiomed BVS5000 and AB5000, Thoratec PVAD and IVAD, Berlin Heart, Levitronix CentriMag, Jarvik 2000 and HeartWare HVAD.
 
== Classification ==


==Design==
VADs are classified according to their operational characteristics. Most VADs operate on similar basic principle i.e., a [[cannula]] is inserted into the [[apex]] of the ventricle. Blood passes through this cannula to a pump and thence through a tube into the [[aorta]] (most commonly [[ascending aorta]]) in case of an LVAD or into the [[pulmonary artery]] in case of an RVAD. The pump is powered through a lead which connects it to a controller and power supply.  In some cases there is also a tube to vent the pump to the outside air. Major distinguishing features between different VADs are the pumps (which vary substantially in method of operation, size and placement), the controller and the materials used for the pump and the associated parts (tubes, cannulas, lead between the pump and the controller/power supply).
===Overview===
Most VADS operate on similar principles. A cannula is inserted into the apex of the appropriate ventricle. Blood passes through this to a pump and thence through a tube to the [[aorta]] in the case of an LVAD or to the [[pulmonary artery]] in the case of an RVAD. The pump is powered through a lead which connects it to a controller and power supply.  In some cases there is also a tube to vent the pump to the outside air. The Jarvik 2000 operates slightly differently - the pump is actually located inside the left ventricle, its outflow passes through the apex of the ventricle to a tube which leads to the aorta.


Major distinguishing features between the different VADS are the pump (which can vary substantially in method of operation, size and placement), the controller, the materials used both for the pump and the associated tubes and cannulas and the lead between the pump and the controller/power supply.
==== First-generation devices ====


===Pumps===
*First generation VADs were large volume-displacement pumps with pulsatile flow generated by electronic or [[pneumatic]] compression of [[blood chambers]].
[[pump|Pumps]] used in VADS can be divided into two main categories - pulsatile pumps, which as the name suggests mimic the natural pulsing action of the heart, and continuous flow pumps<ref name="pmid24280231">{{cite journal| author=Sutcliffe P, Connock M, Pulikottil-Jacob R, Kandala NB, Suri G, Gurung T et al.| title=Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model. | journal=Health Technol Assess | year= 2013 | volume= 17 | issue= 53 | pages= 1-499, v-vi | pmid=24280231 | doi=10.3310/hta17530 | pmc=4781283 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24280231  }} </ref><ref>https://www.openanesthesia.org/ventricular_assist_devices/</ref>.
*Several factors lead to the discontinuation of first generation VADs. These VADs had poor durability due to membrane rupture, bearing, and mechanical valve wear in addition to the higher rate of common VAD complications<ref name="GregoryTimms2011">{{cite journal|last1=Gregory|first1=Shaun D.|last2=Timms|first2=Daniel|last3=Gaddum|first3=Nicholas|last4=Mason|first4=David G.|last5=Fraser|first5=John F.|title=Biventricular Assist Devices: A Technical Review|journal=Annals of Biomedical Engineering|volume=39|issue=9|year=2011|pages=2313–2328|issn=0090-6964|doi=10.1007/s10439-011-0348-8}}</ref>They had large control consoles that significantly reduced [[patient mobility]] and pump that was audible and caused discomfort. These VADs were also associated with higher risk of [[infection]] at external lead, significant [[hemolysis]], [[thrombus]] formation, larger surgical [[incision]] requirement and severe [[postoperative]] [[bleeding]]. Examples include [[Paracorporeal]] Ventricular Assist Device, HeartMate XVE and Novacor.
* First-generation devices are pulsatile volume displacement pumps that use [[pump | positive displacement pumps]]. In some of these pumps the volume occupied by blood varies during the pumping cycle, and if the pump is contained inside the body then a vent tube to the outside air is required. Examples are Berlin Heart EXCOR, Novacor, LionHeart, HeartMate I
* Second-generation devices are axial, continuous flow pumps. Continuous flow VADs normally use either centrifugal pumps or axial flow pump.  Both types have a central rotor containing permanent magnets. Controlled electric currents running through coils contained in the pump housing apply forces to the magnets which cause the rotors to rotate.  In the centrifugal pumps the rotors are shaped to accelerate the blood circumferentially and thus cause it to move towards the outer rim of the pump whereas in the axial flow pumps the rotors are more or less cylindrical with blades that are more or less helical, causing the blood to be accelerated in the direction of the rotor's axis. Examples include MicroMed DeBakey, HeartMate II, Jarvik 2000, TandemHeart
* Third-generation devices are bearingless pumps. An important issue with continuous flow pumps is the method used to suspend the rotor. Early versions used solid bearings however newer pumps, some of which are approved for use in the EU use either electromagnetic or hydrodynamic suspension.  Manufacturers claim that these methods of suspension not only virtually eliminate wear but also reduce damage to blood cells. Third-generation devices are bearingless pumps. Examples include CentriMag, DuraHeart, HeartMate III, Impella


==Effectiveness==
*Paracorporeal Ventricular Assist Device had a pump that was powered pneumatically and placed outside the body. Blood was pulled out of left ventricle through cannulas by a vacuum, passed through a reservoir and returned to aorta creating a pulsatile flow.<ref name="pmid29710092">{{cite journal |vauthors=Miller LW, Rogers JG |title=Evolution of Left Ventricular Assist Device Therapy for Advanced Heart Failure: A Review |journal=JAMA Cardiol |volume=3 |issue=7 |pages=650–658 |date=July 2018 |pmid=29710092 |doi=10.1001/jamacardio.2018.0522 |url=}}</ref>
[[Clinical practice guideline]]s summarize indications<ref name="pmid25851050">{{cite journal| author=Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK et al.| title=2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie D'intervention). | journal=Catheter Cardiovasc Interv | year= 2015 | volume= 85 | issue= 7 | pages= E175-96 | pmid=25851050 | doi=10.1002/ccd.25720 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25851050  }} </ref>.
* HeartMate XVE had a pump that was powered electronically and placed in a pocket in the pre-[[peritoneal]] space. It was smaller in size than Paracorporeal VAD. Due to poor durability and bearing wear, device replacement was required in a significant percentage of patients.<ref name="pmid29710092">{{cite journal |vauthors=Miller LW, Rogers JG |title=Evolution of Left Ventricular Assist Device Therapy for Advanced Heart Failure: A Review |journal=JAMA Cardiol |volume=3 |issue=7 |pages=650–658 |date=July 2018 |pmid=29710092 |doi=10.1001/jamacardio.2018.0522 |url=}}</ref>


[[Systematic review]]s have assessed effectiveness<ref name="pmid24280231">{{cite journal| author=Sutcliffe P, Connock M, Pulikottil-Jacob R, Kandala NB, Suri G, Gurung T et al.| title=Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model. | journal=Health Technol Assess | year= 2013 | volume= 17 | issue= 53 | pages= 1-499, v-vi | pmid=24280231 | doi=10.3310/hta17530 | pmc=4781283 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24280231  }} </ref><ref name="pmid27265673">{{cite journal| author=Briasoulis A, Telila T, Palla M, Mercado N, Kondur A, Grines C et al.| title=Meta-Analysis of Usefulness of Percutaneous Left Ventricular Assist Devices for High-Risk Percutaneous Coronary Interventions. | journal=Am J Cardiol | year= 2016 | volume= 118 | issue= 3 | pages= 369-75 | pmid=27265673 | doi=10.1016/j.amjcard.2016.05.003 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27265673  }} </ref> including comparison of effectiveness to [[intra-aortic balloon pump]]<ref name="pmid31517843">{{cite journal| author=Shi W, Wang W, Wang K, Huang W| title=Percutaneous mechanical circulatory support devices in high-risk patients undergoing percutaneous coronary intervention: A meta-analysis of randomized trials. | journal=Medicine (Baltimore) | year= 2019 | volume= 98 | issue= 37 | pages= e17107 | pmid=31517843 | doi=10.1097/MD.0000000000017107 | pmc=6750338 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31517843  }} </ref>.


Among studies of [[artificial heart]]s, most original studies are not randomized; however, one [[randomized controlled trial]] found a trend, although insignificant, for benefit from the Impella ventricular assist device compare to [[intra-aortic balloon pump]]ing<ref name="pmid22935569">{{cite journal| author=O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J et al.| title=A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. | journal=Circulation | year= 2012 | volume= 126 | issue= 14 | pages= 1717-27 | pmid=22935569 | doi=10.1161/CIRCULATIONAHA.112.098194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22935569  }} </ref>.
==== Second-generation devices ====


==Complications==
*Second Generation VADs are Continuous Flow (CF) devices that use rotary centrifugal, diagonal or axial [[impeller]]s. Although there is marked improvement in design and patient mobility compared to the first generation VADs, their rotary pumps are associated with increased [[thrombogenicity]] and acquired [[platelet]] dysfunction due to the lack of pulsatile flow and high shear forces near the bearings and seals. Commonly used second generation VADs include HeartMate II and Jarvik 2000. These pumps are easier to implant due to their smaller design. These are also quieter and have lower rates of infection and other complications compared to First Generation VADs. <ref name="pmid29763016">{{cite journal |vauthors=Vaidya Y, Patibandla S, Dhamoon AS |title= |journal= |volume= |issue= |pages= |date= |pmid=29763016 |doi= |url=}}</ref>
Because the devices generally result in blood flowing over a non biologic surface, predisposing the blood to [[Coagulation|clotting]], there is need for [[anticoagulation]]. There is one device, the Heartmate, which provides a biologic surface derived from [[fibrin]] and does not require long term anticoagulation; unfortunately, this biologic surface may predispose to infection.
 
*[[HeartMate II]] draws blood from left ventricular apex and pumps it into ascending aorta producing a non-pulsatile flow. It is about the size of a D battery with a rotating impeller which is the shape of an Archimedes screw. Impeller is the only moving part of the pump. Due to lesser adverse events HeartMate II was approved by FDA for BTT in 2008 and later for DT in 2010 due to improved pump durability and minimal damage to blood cells. <ref name="pmid29338999">{{cite journal |vauthors=Stone ME, Pawale A, Ramakrishna H, Weiner MM |title=Implantable Left Ventricular Assist Device Therapy-Recent Advances and Outcomes |journal=J. Cardiothorac. Vasc. Anesth. |volume=32 |issue=4 |pages=2019–2028 |date=August 2018 |pmid=29338999 |doi=10.1053/j.jvca.2017.11.003 |url=}}</ref>
 
*Jarvik 2000 Ventricular Assist System development started in 1987 with several improvements in design since then. The newer Jarvik 2000 pump is a miniaturized [[intraventricular]] pump that is placed in the [[cardiac apex]] with minimally invasive implantation procedures. It creates a blood flow towards the ascending or descending aorta through an outflow conduit and lacks a real inflow conduit. Older pumps required Cardiopulmonary Bypass (CPB) support but less invasive off-pump implantation is done now with or without ExtraCorporeal Membrane Oxygenation ([[ECMO]]) instead of CPB support. <ref name="pmid25452914">{{cite journal |vauthors=Zucchetta F, Tarzia V, Bottio T, Gerosa G |title=The Jarvik-2000 ventricular assist device implantation: how we do it |journal=Ann Cardiothorac Surg |volume=3 |issue=5 |pages=525–31 |date=September 2014 |pmid=25452914 |pmc=4229469 |doi=10.3978/j.issn.2225-319X.2014.09.09 |url=}}</ref>
 
==== Third-generation devices ====
 
*Third Generation VADs are Continuous Flow (CF) centrifugal pumps that use contactless/bearingless impeller drive and suspension systems and hence, completely eliminate mechanical wear of the pump components. Impeller is levitated by electromagnetic and/or [[hydrodynamic]] forces while active electromagnetic forces are employed to rotate the impeller. These VADs are more durable, easier to implant and have lower risk of [[thrombosis]] and [[hemolysis]]. Examples include HeartMate III and HeartWare HVAD.  <ref name="pmid29763016">{{cite journal |vauthors=Vaidya Y, Patibandla S, Dhamoon AS |title= |journal= |volume= |issue= |pages= |date= |pmid=29763016 |doi= |url=}}</ref>


VAD-related [[infection]] can be caused by a large number of different organisms:<ref>{{cite journal | journal=Lancet Infect Dis | author=Gordon RJ, Quagliarello B, Lowy FD | title=Ventricular assist device-related infections | year=2006 | volume=6 | issue=7 | pages=426&ndash;37 }}</ref>
*[[HeartMate III]] is the newer LVAD technology that has shown to have fewer complications like [[strokes]], major bleeding, [[GI bleeding]] or [[ventricular arrhythmias]] when compared to HeartMate II. Fewer pump thromboses and LVAD replacements for LVAD malfunction have also been reported with this newest LVAD. The improved function of HeartMate III is due to it's higher [[hemocompatibility]]. It has wide blood flow conduits which reduce shear of the blood.<ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref> It's frictionless design without mechanical bearings not only reduces wear-and-tear but also decreases the amount of heat produced during impeller rotation. <ref name="StonePawale2018">{{cite journal|last1=Stone|first1=Marc E.|last2=Pawale|first2=Amit|last3=Ramakrishna|first3=Harish|last4=Weiner|first4=Menachem M.|title=Implantable Left Ventricular Assist Device Therapy—Recent Advances and Outcomes|journal=Journal of Cardiothoracic and Vascular Anesthesia|volume=32|issue=4|year=2018|pages=2019–2028|issn=10530770|doi=10.1053/j.jvca.2017.11.003}}</ref>
* Gram positive bacteria (''Staphylococci'' especially ''[[Staphylococcus aureus|Staph. aureus]]'', [[Enterococci]])
* Gram negative bacteria (''[[Pseudomonas aeruginosa]]'', ''Enterobacter'' species, ''[[Klebsiella]]'' species)
* Fungi especially Candida sp.


Treatment of VAD-related infection is exceedingly difficult and many patients die of infection despite optimal treatment. Initial treatment should be with broad spectrum antibiotics, but every effort must be made to obtain appropriate samples for culture. A final decision regarding antibiotic therapy must be based on the results of microbiogical cultures.
*[[HeartWare]] HVAD is placed intra[[pericardially]] in the left ventricular apex. It has a bearingless magnetically driven impeller. It is suitable for patients with smaller [[body surface area]]. Due to its small size, it has also been used as an implantable RVAD.<ref name="pmid29338999">{{cite journal |vauthors=Stone ME, Pawale A, Ramakrishna H, Weiner MM |title=Implantable Left Ventricular Assist Device Therapy-Recent Advances and Outcomes |journal=J. Cardiothorac. Vasc. Anesth. |volume=32 |issue=4 |pages=2019–2028 |date=August 2018 |pmid=29338999 |doi=10.1053/j.jvca.2017.11.003 |url=}}</ref>


Other problems include [[immunosuppression]], clotting with resultant [[stroke]], and [[bleeding]] secondary to anticoagulation. It is interesting to note that some of the [[polyurethane]] components used in the devices cause the deletion of a subset of [[White blood cell|immune cells]] when blood comes in contact with them. This predisposes the patient to [[fungus|fungal]] and some [[virus|viral]] infections necessitating appropriate [[Prophylaxis|prophylactic therapy]].
== Indications ==
VADs can be used for the following conditions: <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* Bridge-to-Transplant (BTT): Patients who are [[transplant]] eligible and need a [[donor]] heart for survival.
* Destination therapy (DT): Patients who need mechanical circulatory support as an alternative to heart transplant.
* Bridge-to-Decision (BTD): Patients who are not assigned the need for heart transplant at the time of implantation.
* Bridge-to-Candidacy (BTC): Patients who are not transplant eligible but may be reconsidered for transplant after a [[temporary circulatory support]].
* Bridge-to-Recovery (BTR): Patients who require temporary circulatory support after an acute insult to [[cardiac]] function, like [[cardiogenic shock]].


==History==
Modern [[indications]] for short-term use of MCS include: <ref name="StonePawale2018">{{cite journal|last1=Stone|first1=Marc E.|last2=Pawale|first2=Amit|last3=Ramakrishna|first3=Harish|last4=Weiner|first4=Menachem M.|title=Implantable Left Ventricular Assist Device Therapy—Recent Advances and Outcomes|journal=Journal of Cardiothoracic and Vascular Anesthesia|volume=32|issue=4|year=2018|pages=2019–2028|issn=10530770|doi=10.1053/j.jvca.2017.11.003}}</ref>
The early VADs emulated the heart by using a "pulsatile" action where blood is alternately sucked into the pump from the left ventricle then forced out into the aorta. Devices of this kind include the Heartmate, which was approved for use in the US by the FDA in October 1994. These devices are commonly referred to as first generation VADs


More recent work has concentrated on continuous flow pumps, which can be roughly categorized as either centrifugal pumps or axial flow impeller driven pumps.  These pumps have the advantage of greater simplicity resulting in smaller size and greater reliability.  These devices are  referred to as second generation VADs. A side effect is that their users need to carry documentation saying that the lack of a pulse does not mean that they are dead.
*Bridge-to-immediate survival
*Brdige-to-next decision
*Bridge-to-bridge
*Bridge-to-surgery


Third generation VADs suspend the impeller in the pump using either hydrodynamic or electromagnetic suspension, thus removing the need for bearings and reducing the number of moving parts to one.
== Contraindications ==


Another technology undergoing clinical trials is the use of trans cutaneous induction to power and control the device rather than using percutaneous cables. Apart from the obvious cosmetic advantage this reduces the risk of infection and the consequent need to take preventative action. A pulsatile pump using this technology has CE Mark approval and is in clinical trials for US FDA approval.
* Coexisting severe [[comorbidity]] like irreversible [[hepatic]], [[renal]], or [[neurological]] disease <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* Patient [[non-compliance]] <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* Severe [[psychosocial]] limitations (Unmanaged psychiatric disorders, lack of social support) <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* [[Aortic regurgitation]] (in case of LVAD) and [[Pulmonary regurgitation]] (in case of RVAD) <ref name="pmid30093192">{{cite journal |vauthors=Pieri M, Pappalardo F |title=Impella RP in the Treatment of Right Ventricular Failure: What We Know and Where We Go |journal=J. Cardiothorac. Vasc. Anesth. |volume=32 |issue=5 |pages=2339–2343 |date=October 2018 |pmid=30093192 |doi=10.1053/j.jvca.2018.06.007 |url=}}</ref>
* Limited life expectancy (age >80 for DT, untreated [[malignancy]]) <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* [[Poor nutritional status]] ([[obesity]] or [[malnutrition]]) <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* Limitations to [[rehabilitation]] ([[musculoskeletal]] disease, severe [[peripheral vascular disease]], active [[substance abuse]], active infection, prolonged [[intubation]]) <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>


A very different approach in the early stages of development is the use of an inflatable cuff around the aorta. Inflating the cuff contracts the aorta and deflating the cuff allows the aorta to expand - in effect the aorta becomes a second left ventricle. A proposed refinement is to use the patient's skeletal muscle, driven by a pacemaker, to power this device which would make it truly self contained. In any case it has substantial potential advantages in avoiding the need to operate on the heart itself and in avoiding any contact between blood and the device. Interestingly this approach involves a return to a pulsatile flow.
==Complications==
* '''Right Ventricular(RV) failure:'''
Unloading of the [[left ventricle]] post-LVAD implantation may result in [[septal]] shifts, leading to increased RV [[preload]], decreased RV [[contractility]] and function. RVAD implantation may be necessary until RV function improves, at which point RVAD can be explanted. <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* '''Bleeding:'''
Bleeding is a common complication during the implantation procedure. Patients with Continuous Flow VADs are systemically [[anticoagulated]] with [[Warfarin]], which further increases the risk of bleeding, particularly Gastro-intestial (GI) Bleed. Patients should be evaluated and if possible, treated preoperatively for [[GI bleeding]] sources such as [[colonic polyps]], stomach [[ulcers]] and [[angiodysplasia]]s. There is also a higher risk of bleeding post-LVAD implantation from degradation of [[Von-Willebrand Factor]] ([[VWF]]) by VAD rotors, which is reversible once LVAD is removed.<ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* '''Thromboemolic events and Stroke:'''
There is an increased risk of [[thromboembolic]] events and [[Transient Ischemic Attacks]] ([[TIA]]s)in patients with Continous Flow VADs despite of systemic anticoagulation. If pump thrombosis develops, there might be an emergent need for pump exchange and moving the patient up on priority list of heart transplant. <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* '''Infection:'''
Infection at multiple sites of VAD circuit is a common complication. These sites include the VAD pocket where the VAD is implanted, the VAD itself or the cannulas that go from the ventricle to the VAD and from the VAD to the aorta. The most common infection site is the driveline which goes from the VAD through the skin to the VAD power source since it is a pathway from the external environment to the VAD interior. Common [[causative]] organisms in driveline infections are the [[skin flora]] such as ''[[Staphylococcus aureus]]'' and [[coagulase-negative staphylococci]] and in infection of internal components are ''[[Serratia]], [[Klebsiella]]'', and ''[[Enteroccocus]]'' species, ''[[Pseudomonas aeruginosa]]''. ''[[Candida]]'' can cause up to ten percent of infections. Treatment includes [[debridement]] of infected [[tissue]] and administration of [[intravenous]] [[antibiotics]]. Explantantion of infected LVAD is sometimes necessary. <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* '''Ventricular arrythmias:'''
Ventricular [[arrythmias]] is a common complication after LVAD implantation. It is thought to be from [[re-entrant]] circuits that are formed around the site of the inflow cannula in already damaged [[myocardium]]. Implantable cardioverter-defibrillator helps with these arrhythmias until the ventricles remodel as the time goes on. [[Anti-arrhythmic]] agents such as [[lidocaine]] or [[amiodarone]] are rarely necessary. <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* '''Device Malfunction and Optimization:'''
Malfunction of different parts of VAD ( driveline, controller, pump) can cause the device to stop working.<ref name="pmid29907277">{{cite journal |vauthors=Emani S |title=Complications of Durable Left Ventricular Assist Device Therapy |journal=Crit Care Clin |volume=34 |issue=3 |pages=465–477 |date=July 2018 |pmid=29907277 |doi=10.1016/j.ccc.2018.03.003 |url=}}</ref> VADs are complex devices that need an expert to operate them in order to obtain optimal right and left ventricular [[hemodynamics]].<ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>
* '''Valvular Insufficiency:'''
[[Mitral]] and [[Aortic valve]] insufficiency can be seen post-LVAD implantation. This can effect pump function and may worsen heart failure. <ref name="pmid29907277">{{cite journal |vauthors=Emani S |title=Complications of Durable Left Ventricular Assist Device Therapy |journal=Crit Care Clin |volume=34 |issue=3 |pages=465–477 |date=July 2018 |pmid=29907277 |doi=10.1016/j.ccc.2018.03.003 |url=}}</ref>


==Images: Ventricular Assist Devices==
==Images: Ventricular Assist Devices==


<gallery perRow="3">
<gallery perrow="3">
Image:Biventricular assist device CT 001.jpg|Biventricular assist device
Image:Biventricular assist device CT 001.jpg|Biventricular assist device
Image:Biventricular assist device CT 002.jpg|Biventricular assist device
Image:Biventricular assist device CT 002.jpg|Biventricular assist device
Line 76: Line 127:
Image:Biventricular assist device CT 008.jpg|Biventricular assist device
Image:Biventricular assist device CT 008.jpg|Biventricular assist device
</gallery>
</gallery>
==Recent advances in LVAD Therapy with Percutaneous LVADs==
Recent developments in LVAD therapy have been made to provide short-term temporary [[MCS]] to patients in [[cardiogenic shock]]. [[Axillary artery]] is commonly being used for insertion of temporary VADs to allow for improved patient mobility. <ref name="pmid29710092">{{cite journal |vauthors=Miller LW, Rogers JG |title=Evolution of Left Ventricular Assist Device Therapy for Advanced Heart Failure: A Review |journal=JAMA Cardiol |volume=3 |issue=7 |pages=650–658 |date=July 2018 |pmid=29710092 |doi=10.1001/jamacardio.2018.0522 |url=}}</ref>
*[[Intra-aortic balloon pump]] was the first temporary VAD that is still being used.
*[[ExtraCorporeal Membrane Oxygenation]] ([[ECMO]]) is being used to provide cardiac and pulmonary support.
*[[Tandem Heart]] is a [[left atrial]] to [[iliofemoral artery]] bypass pump.
*[[Impella]] is an axial flow pump with non-pulsatile blood flow from left ventricle to ascending aorta.
==Fully Implantable Pumps==
Most VADs currently being used are not fully implantable since they connect to an external power source, hence increasing the risk of infection. Fully implantable devices could reduce this risk of infection. The newest totally implantable LVAD ([[Leviticus]] [[FiVAD]]) uses the [[Jarvik]] VAD platform and is undergoing [[clinical trials]]. <ref name="pmid31243930">{{cite journal |vauthors=Eisen HJ |title=Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications |journal=Korean Circ J |volume=49 |issue=7 |pages=568–585 |date=July 2019 |pmid=31243930 |pmc=6597447 |doi=10.4070/kcj.2019.0161 |url=}}</ref>


== List of implantable VAD devices ==
== List of implantable VAD devices ==

Latest revision as of 19:29, 6 July 2020

WikiDoc Resources for Ventricular assist device

Articles

Most recent articles on Ventricular assist device

Most cited articles on Ventricular assist device

Review articles on Ventricular assist device

Articles on Ventricular assist device in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ventricular assist device

Images of Ventricular assist device

Photos of Ventricular assist device

Podcasts & MP3s on Ventricular assist device

Videos on Ventricular assist device

Evidence Based Medicine

Cochrane Collaboration on Ventricular assist device

Bandolier on Ventricular assist device

TRIP on Ventricular assist device

Clinical Trials

Ongoing Trials on Ventricular assist device at Clinical Trials.gov

Trial results on Ventricular assist device

Clinical Trials on Ventricular assist device at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ventricular assist device

NICE Guidance on Ventricular assist device

NHS PRODIGY Guidance

FDA on Ventricular assist device

CDC on Ventricular assist device

Books

Books on Ventricular assist device

News

Ventricular assist device in the news

Be alerted to news on Ventricular assist device

News trends on Ventricular assist device

Commentary

Blogs on Ventricular assist device

Definitions

Definitions of Ventricular assist device

Patient Resources / Community

Patient resources on Ventricular assist device

Discussion groups on Ventricular assist device

Patient Handouts on Ventricular assist device

Directions to Hospitals Treating Ventricular assist device

Risk calculators and risk factors for Ventricular assist device

Healthcare Provider Resources

Symptoms of Ventricular assist device

Causes & Risk Factors for Ventricular assist device

Diagnostic studies for Ventricular assist device

Treatment of Ventricular assist device

Continuing Medical Education (CME)

CME Programs on Ventricular assist device

International

Ventricular assist device en Espanol

Ventricular assist device en Francais

Business

Ventricular assist device in the Marketplace

Patents on Ventricular assist device

Experimental / Informatics

List of terms related to Ventricular assist device

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Marv Slepian, M.D.; University of Arizona [2]; Juan A. Sanchez MD MPA [3], Chairman, The Stanley J. Dudrick Department of Surgery, Saint Mary's Hospital, Waterbury, CT, Tayebah Chaudhry[4], Syed Hassan A. Kazmi BSc, MD [5]


Overview

Ventricular assist device (VAD) is a mechanical device that provides Mechanical Circulatory Support (MCS) in patients with advanced heart failure. VAD therapy has shown improved outcome and survival in heart failure patients compared to pharmacological therapy alone. These devices are commonly used as a Bridge-to-Transplant (BTT) in heart transplant eligible patients or as a Destination Therapy (DT) in patients ineligible for heart transplant. VADs are indicated for either short-term use in patients recovering from heart attacks or heart surgery or for long-term use (months to years and in some cases for life) in patients suffering from end-stage heart failure.

Over the years, significant development has been made to create miniaturized VADs with increased durability, reliability and lesser noise emission. Newer (third generation) VADs are Continuous Flow (CF) pumps with lesser complications compared to the older (first generation) VADs that were large and had pulsatile-flow pumps. Depending on the heart chamber that needs MCS, VADs can be used as Left Ventricular Assist Devices (LVADs), Right Ventricular Assist Devices (RVADs) or BiVentricular Assist Devices (BiVADs).

Some VADs are percutaneous or transcutaneous (Impella, TandemHeart) while others are implantable (HeartMate II, HeartMate III), that allow patients to be fully mobile.

Ongoing research in VAD development is being focused on eliminating the need for a driveline, better surgical approaches and strategies for telemetric assessment of device function and remote charging of batteries.

History

VADs evolved over time after an external technology was used to provide cardiovascular support to a patient with Cardiopulmonary bypass (CPB) in an atrial septal defect repair surgery by John Gibbons. This lead to further interest and efforts to developing an artificial heart and later implantation of VAD in the late 1960s. Thoratec pneumatic VAD was the first Food and Drug Administration (FDA) approved VAD used as a BTT. This technology further evolved into HeartMate I, but more work needed to be done to develop newer LVADs with lesser complications. The Second and Third Generation VADs were designed to have a continuous flow rather than pulsatile. [1]

Types of Ventricular Assist Devices (VADs)

VADs are implanted in one ventricle or both ventricles of heart.

Left Ventricular Assist Device (LVAD)

  • LVADs are the most commonly implanted VADs in end-stage heart failure patients. With robust innovation in technology, LVADs have significantly increased patient survival despite the adverse events associated with the devices. This has lead to growing proportion of patients undergoing LVAD implantations as a Destination therapy.
  • HeartMate II, HeartMate III and HeartWare HVAD are the only commercially FDA- approved LVADs for adults in North America. Worldwide efforts are being made to create the most effective and safest interface including the INCOR, Jarvik 2000, EVAHEART LVAS and more. [2]

Right Ventricular Assist Device (RVAD)

BiVentricular Assist Device (BiVAD)

  • BiVAD is used to provide simultaneous MCS to both ventricles of heart. It is different from Total Artificial Heart (TAF) since it works in parallel to the native heart and removal of native heart is not required. Hence, BiVAD provides a potential for myocardial recovery of the retained native heart and reduces the need for a donor heart.[4]
  • Examples of VADs implanted as BiVAD include Abiomed BVS5000 and AB5000, Thoratec PVAD and IVAD, Berlin Heart, Levitronix CentriMag, Jarvik 2000 and HeartWare HVAD.

Classification

VADs are classified according to their operational characteristics. Most VADs operate on similar basic principle i.e., a cannula is inserted into the apex of the ventricle. Blood passes through this cannula to a pump and thence through a tube into the aorta (most commonly ascending aorta) in case of an LVAD or into the pulmonary artery in case of an RVAD. The pump is powered through a lead which connects it to a controller and power supply. In some cases there is also a tube to vent the pump to the outside air. Major distinguishing features between different VADs are the pumps (which vary substantially in method of operation, size and placement), the controller and the materials used for the pump and the associated parts (tubes, cannulas, lead between the pump and the controller/power supply).

First-generation devices

  • First generation VADs were large volume-displacement pumps with pulsatile flow generated by electronic or pneumatic compression of blood chambers.
  • Several factors lead to the discontinuation of first generation VADs. These VADs had poor durability due to membrane rupture, bearing, and mechanical valve wear in addition to the higher rate of common VAD complications[4]They had large control consoles that significantly reduced patient mobility and pump that was audible and caused discomfort. These VADs were also associated with higher risk of infection at external lead, significant hemolysis, thrombus formation, larger surgical incision requirement and severe postoperative bleeding. Examples include Paracorporeal Ventricular Assist Device, HeartMate XVE and Novacor.
  • Paracorporeal Ventricular Assist Device had a pump that was powered pneumatically and placed outside the body. Blood was pulled out of left ventricle through cannulas by a vacuum, passed through a reservoir and returned to aorta creating a pulsatile flow.[6]
  • HeartMate XVE had a pump that was powered electronically and placed in a pocket in the pre-peritoneal space. It was smaller in size than Paracorporeal VAD. Due to poor durability and bearing wear, device replacement was required in a significant percentage of patients.[6]


Second-generation devices

  • Second Generation VADs are Continuous Flow (CF) devices that use rotary centrifugal, diagonal or axial impellers. Although there is marked improvement in design and patient mobility compared to the first generation VADs, their rotary pumps are associated with increased thrombogenicity and acquired platelet dysfunction due to the lack of pulsatile flow and high shear forces near the bearings and seals. Commonly used second generation VADs include HeartMate II and Jarvik 2000. These pumps are easier to implant due to their smaller design. These are also quieter and have lower rates of infection and other complications compared to First Generation VADs. [7]
  • HeartMate II draws blood from left ventricular apex and pumps it into ascending aorta producing a non-pulsatile flow. It is about the size of a D battery with a rotating impeller which is the shape of an Archimedes screw. Impeller is the only moving part of the pump. Due to lesser adverse events HeartMate II was approved by FDA for BTT in 2008 and later for DT in 2010 due to improved pump durability and minimal damage to blood cells. [8]
  • Jarvik 2000 Ventricular Assist System development started in 1987 with several improvements in design since then. The newer Jarvik 2000 pump is a miniaturized intraventricular pump that is placed in the cardiac apex with minimally invasive implantation procedures. It creates a blood flow towards the ascending or descending aorta through an outflow conduit and lacks a real inflow conduit. Older pumps required Cardiopulmonary Bypass (CPB) support but less invasive off-pump implantation is done now with or without ExtraCorporeal Membrane Oxygenation (ECMO) instead of CPB support. [9]

Third-generation devices

  • Third Generation VADs are Continuous Flow (CF) centrifugal pumps that use contactless/bearingless impeller drive and suspension systems and hence, completely eliminate mechanical wear of the pump components. Impeller is levitated by electromagnetic and/or hydrodynamic forces while active electromagnetic forces are employed to rotate the impeller. These VADs are more durable, easier to implant and have lower risk of thrombosis and hemolysis. Examples include HeartMate III and HeartWare HVAD. [7]
  • HeartMate III is the newer LVAD technology that has shown to have fewer complications like strokes, major bleeding, GI bleeding or ventricular arrhythmias when compared to HeartMate II. Fewer pump thromboses and LVAD replacements for LVAD malfunction have also been reported with this newest LVAD. The improved function of HeartMate III is due to it's higher hemocompatibility. It has wide blood flow conduits which reduce shear of the blood.[1] It's frictionless design without mechanical bearings not only reduces wear-and-tear but also decreases the amount of heat produced during impeller rotation. [10]
  • HeartWare HVAD is placed intrapericardially in the left ventricular apex. It has a bearingless magnetically driven impeller. It is suitable for patients with smaller body surface area. Due to its small size, it has also been used as an implantable RVAD.[8]

Indications

VADs can be used for the following conditions: [1]

  • Bridge-to-Transplant (BTT): Patients who are transplant eligible and need a donor heart for survival.
  • Destination therapy (DT): Patients who need mechanical circulatory support as an alternative to heart transplant.
  • Bridge-to-Decision (BTD): Patients who are not assigned the need for heart transplant at the time of implantation.
  • Bridge-to-Candidacy (BTC): Patients who are not transplant eligible but may be reconsidered for transplant after a temporary circulatory support.
  • Bridge-to-Recovery (BTR): Patients who require temporary circulatory support after an acute insult to cardiac function, like cardiogenic shock.

Modern indications for short-term use of MCS include: [10]

  • Bridge-to-immediate survival
  • Brdige-to-next decision
  • Bridge-to-bridge
  • Bridge-to-surgery

Contraindications

Complications

  • Right Ventricular(RV) failure:

Unloading of the left ventricle post-LVAD implantation may result in septal shifts, leading to increased RV preload, decreased RV contractility and function. RVAD implantation may be necessary until RV function improves, at which point RVAD can be explanted. [1]

  • Bleeding:

Bleeding is a common complication during the implantation procedure. Patients with Continuous Flow VADs are systemically anticoagulated with Warfarin, which further increases the risk of bleeding, particularly Gastro-intestial (GI) Bleed. Patients should be evaluated and if possible, treated preoperatively for GI bleeding sources such as colonic polyps, stomach ulcers and angiodysplasias. There is also a higher risk of bleeding post-LVAD implantation from degradation of Von-Willebrand Factor (VWF) by VAD rotors, which is reversible once LVAD is removed.[1]

  • Thromboemolic events and Stroke:

There is an increased risk of thromboembolic events and Transient Ischemic Attacks (TIAs)in patients with Continous Flow VADs despite of systemic anticoagulation. If pump thrombosis develops, there might be an emergent need for pump exchange and moving the patient up on priority list of heart transplant. [1]

  • Infection:

Infection at multiple sites of VAD circuit is a common complication. These sites include the VAD pocket where the VAD is implanted, the VAD itself or the cannulas that go from the ventricle to the VAD and from the VAD to the aorta. The most common infection site is the driveline which goes from the VAD through the skin to the VAD power source since it is a pathway from the external environment to the VAD interior. Common causative organisms in driveline infections are the skin flora such as Staphylococcus aureus and coagulase-negative staphylococci and in infection of internal components are Serratia, Klebsiella, and Enteroccocus species, Pseudomonas aeruginosa. Candida can cause up to ten percent of infections. Treatment includes debridement of infected tissue and administration of intravenous antibiotics. Explantantion of infected LVAD is sometimes necessary. [1]

  • Ventricular arrythmias:

Ventricular arrythmias is a common complication after LVAD implantation. It is thought to be from re-entrant circuits that are formed around the site of the inflow cannula in already damaged myocardium. Implantable cardioverter-defibrillator helps with these arrhythmias until the ventricles remodel as the time goes on. Anti-arrhythmic agents such as lidocaine or amiodarone are rarely necessary. [1]

  • Device Malfunction and Optimization:

Malfunction of different parts of VAD ( driveline, controller, pump) can cause the device to stop working.[11] VADs are complex devices that need an expert to operate them in order to obtain optimal right and left ventricular hemodynamics.[1]

  • Valvular Insufficiency:

Mitral and Aortic valve insufficiency can be seen post-LVAD implantation. This can effect pump function and may worsen heart failure. [11]

Images: Ventricular Assist Devices

  • Biventricular assist device

    Biventricular assist device

  • Biventricular assist device

    Biventricular assist device

  • Biventricular assist device

    Biventricular assist device

  • Biventricular assist device

    Biventricular assist device

  • Biventricular assist device

    Biventricular assist device

  • Biventricular assist device

    Biventricular assist device

  • Biventricular assist device

    Biventricular assist device

  • Biventricular assist device

    Biventricular assist device

Recent advances in LVAD Therapy with Percutaneous LVADs

Recent developments in LVAD therapy have been made to provide short-term temporary MCS to patients in cardiogenic shock. Axillary artery is commonly being used for insertion of temporary VADs to allow for improved patient mobility. [6]

Fully Implantable Pumps

Most VADs currently being used are not fully implantable since they connect to an external power source, hence increasing the risk of infection. Fully implantable devices could reduce this risk of infection. The newest totally implantable LVAD (Leviticus FiVAD) uses the Jarvik VAD platform and is undergoing clinical trials. [1]

List of implantable VAD devices

This is a partial list and may never be complete
Referenced additions are welcome

Device Manufacturer Type Approval Status as at December 2007
Novacor World Heart Pulsatile Approved for use in North America, European Union and Japan
Heartmate Thoratec Pulsatile Approved for use in North America
Heartmate II Thoratec Rotor driven continuous axial flow, ball and cup bearings. Approved for use in European Union. FDA approval for bridge to transplant achieved November 2007.
Incor Berlin Heart Continuous flow driven by a magnetically suspended axial flow rotor. Approved for use in European Union.
Jarvik 2000 Jarvik Heart Continuous flow, axial rotor supported by ceramic bearings Approved for use in the European Union. Clinical trials for FDA approval are planned.
MicroMed DeBakey VAD MicroMed Continuous flow driven by axial rotor supported by ceramic bearings Approved for use in the European Union. The child version is approved for use in children in USA. Undergoing clinical trials in USA for FDA approval.
VentrAssist Ventracor Continuous flow driven by a hydrodynamically suspended centrifugal rotor. Approved for use in European Union and Australia. Undergoing clinical trials for FDA approval
MTIHeartLVAD MiTiHeart Corporation Continuous flow driven by a magnetically suspended centrifugal rotor. Yet to start clinical trials.
C-Pulse Sunshine Heart Pulsatile, driven by an inflatable cuff around the aorta Yet to start clinical trials
HVAD HeartWare Similar to Ventracor - magnetic impellor similar to BLDCmotor undergoing clinical trials for CE, applied to start FDA US trials



References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 Eisen HJ (July 2019). "Left Ventricular Assist Devices (LVADS): History, Clinical Application and Complications". Korean Circ J. 49 (7): 568–585. doi:10.4070/kcj.2019.0161. PMC 6597447 Check |pmc= value (help). PMID 31243930.
  2. ↑ Han JJ, Acker MA, Atluri P (December 2018). "Left Ventricular Assist Devices". Circulation. 138 (24): 2841–2851. doi:10.1161/CIRCULATIONAHA.118.035566. PMID 30565993.
  3. ↑ 3.0 3.1 Pieri M, Pappalardo F (October 2018). "Impella RP in the Treatment of Right Ventricular Failure: What We Know and Where We Go". J. Cardiothorac. Vasc. Anesth. 32 (5): 2339–2343. doi:10.1053/j.jvca.2018.06.007. PMID 30093192.
  4. ↑ 4.0 4.1 Gregory, Shaun D.; Timms, Daniel; Gaddum, Nicholas; Mason, David G.; Fraser, John F. (2011). "Biventricular Assist Devices: A Technical Review". Annals of Biomedical Engineering. 39 (9): 2313–2328. doi:10.1007/s10439-011-0348-8. ISSN 0090-6964.
  5. ↑ Hayward, Christopher S; Shehab, Sajad (2019). "Choosing Between Left Ventricular Assist Devices and Biventricular Assist Devices". Cardiac Failure Review. 5 (1): 19. doi:10.15420/cfr.2018.23.2. ISSN 2057-7540.
  6. ↑ 6.0 6.1 6.2 Miller LW, Rogers JG (July 2018). "Evolution of Left Ventricular Assist Device Therapy for Advanced Heart Failure: A Review". JAMA Cardiol. 3 (7): 650–658. doi:10.1001/jamacardio.2018.0522. PMID 29710092.
  7. ↑ 7.0 7.1 Vaidya Y, Patibandla S, Dhamoon AS. PMID 29763016. Missing or empty |title= (help)
  8. ↑ 8.0 8.1 Stone ME, Pawale A, Ramakrishna H, Weiner MM (August 2018). "Implantable Left Ventricular Assist Device Therapy-Recent Advances and Outcomes". J. Cardiothorac. Vasc. Anesth. 32 (4): 2019–2028. doi:10.1053/j.jvca.2017.11.003. PMID 29338999.
  9. ↑ Zucchetta F, Tarzia V, Bottio T, Gerosa G (September 2014). "The Jarvik-2000 ventricular assist device implantation: how we do it". Ann Cardiothorac Surg. 3 (5): 525–31. doi:10.3978/j.issn.2225-319X.2014.09.09. PMC 4229469. PMID 25452914.
  10. ↑ 10.0 10.1 Stone, Marc E.; Pawale, Amit; Ramakrishna, Harish; Weiner, Menachem M. (2018). "Implantable Left Ventricular Assist Device Therapy—Recent Advances and Outcomes". Journal of Cardiothoracic and Vascular Anesthesia. 32 (4): 2019–2028. doi:10.1053/j.jvca.2017.11.003. ISSN 1053-0770.
  11. ↑ 11.0 11.1 Emani S (July 2018). "Complications of Durable Left Ventricular Assist Device Therapy". Crit Care Clin. 34 (3): 465–477. doi:10.1016/j.ccc.2018.03.003. PMID 29907277.

External links

uk:Шлуночковий допоміжний пристрій

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Ventricular_assist_device&oldid=1621919"